Gerard Short has joined VarmX BV of the Netherlands as chief medical officer. He will be responsible for overseeing clinical development of the biotech company’s pipeline of products for the reversal of anticoagulation. Dr Short has focused on rare diseases and gene therapies, and joins VarmX after five years at Freeline Therapeutics where he grew the medical, clinical, and regulatory groups, and advanced gene therapy programmes in haemophilia B and Fabry’s disease. Dr Short qualified in medicine at St. Mary’s Hospital Medical School in London, and holds an MBA from London Business School, UK.
VarmX announced the appointment on 27 January 2021
Copyright 2021 Evernow Publishing Ltd.